STAT+: Incyte pancreatic cancer medicine induces lasting tumor responses, company says at ESMO
MADRID — A targeted drug from Incyte, when used in combination with chemotherapy, induced lasting tumor responses in certain patients with pancreatic cancer — results, the biotech said, that support its prior decision to advance the treatment into…
ImpactMinor 15/100
Why it mattersnimble: low (p 0.70)
RegionsGlobal
Published23 h ago (Mon, 26 Oct 2026 13:57:14 GMT)
RetrievedMon, 26 Oct 2026 14:00:31 GMT via rss
ClassifiedMon, 26 Oct 2026 14:02:01 GMT by nimble
AuthorAdam Feuerstein